MIR4695

Across TCGA pan-cancer cohorts, MIR4695 RNA is linked to patient survival in 4 of 34 cancer types, making it the most broadly survival-associated MIR4695 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MIR4695 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR4695 expression acts as an unfavorable survival marker.

LIHC, PAAD, and LUSC are the cancer types where MIR4695 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.241	0.552	<.001	99	view →
PAAD	DFS	Tertile	All	0.100	0.484	.003	36	view →
LUSC	OS	Tertile	All	0.283	0.663	.021	33	view →
KIRC	OS	Tertile	All	0.438	0.661	.012	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MIR4695–LIHC (DFS)

Open the LIHC breakdown →